Understand the source comparison
Tesofensine vs Other Metabolic Modulators: Research Comparison
Tesofensine Triple monoamine reuptake inhibitor (DAT/NET/SERT) 10–15% above baseline Favors fat oxidation (RER ~0.75) 4–5 weeks CNS-peripheral energy integration, thermogenesis modeling, metabolic adaptation studies Clenbuterol Beta-2 adrenergic agonist 5–8% a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tesofensine
- Triple monoamine reuptake inhibitor (DAT/NET/SERT)
- 10–15% above baseline
- Favors fat oxidation (RER ~0.75)
- 4–5 weeks
- CNS-peripheral energy integration, thermogenesis modeling, metabolic adaptation studies
- Clenbuterol
- Beta-2 adrenergic agonist
- 5–8% above baseline
- Minimal substrate shift
- 1–2 weeks
- Isolated thermogenesis, receptor downregulation studies
- GLP-1 analogs (semaglutide, liraglutide)
- Incretin receptor agonist
- 2–5% (indirect via reduced intake)
- No direct shift. Caloric restriction effect
- 8–12 weeks
- Appetite-energy balance, gastric emptying, glucose metabolism
- Ephedrine + Caffeine (EC stack)
- NET inhibitor + adenosine antagonist
- 8–12% above baseline
- Moderate fat oxidation preference
- 2–3 weeks
- Sympathomimetic thermogenesis, short-term metabolic boost
- Sibutramine (withdrawn)
- NET/SERT reuptake inhibitor
- 8–10% above baseline
- Moderate fat oxidation
- 3–4 weeks
- Historical comparator. No longer available for new research
- Bottom Line
- Tesofensine provides the only current triple-monoamine model with sustained thermogenic effects, making it irreplaceable for studies requiring simultaneous CNS appetite regulation and peripheral metabolic activation.